•Corbus Pharmaceuticals announced the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer, bringing over 20 years of industry experience.
•The company plans to initiate a registrational study for CRB-701 and expects Phase 1b obesity study results in late summer 2026.
